JP Morgan Downgrades NovoCure to Underweight, Lowers Price Target to $50
JP Morgan analyst Jessica Fye downgrades NovoCure (NASDAQ:NVCR) from Neutral to Underweight and lowers the price target from $99 to $50.
Truist Securities Downgrades Veeva Sys to Hold, Lowers Price Target to $195
Truist Securities analyst Joe Meares downgrades Veeva Sys (NYSE:VEEV) from Buy to Hold and lowers the price target from $205 to $195.
Exane BNP Paribas Downgrades Qualtrics International to Neutral, Announces $18.2 Price Target
Exane BNP Paribas analyst Stefan Slowinski downgrades Qualtrics International (NASDAQ:XM) from Outperform to Neutral and announces $18.2 price target.
B of A Securities Downgrades Terex to Neutral, Lowers Price Target to $54
B of A Securities analyst Michael Feniger downgrades Terex (NYSE:TEX) from Buy to Neutral and lowers the price target from $66 to $54.
Oppenheimer Downgrades RingCentral to Perform
Oppenheimer analyst Timothy Horan downgrades RingCentral (NYSE:RNG) from Outperform to Perform.
Cantor Fitzgerald Downgrades REE Automotive to Neutral, Lowers Price Target to $1
Cantor Fitzgerald analyst Andres Sheppard downgrades REE Automotive (NASDAQ:REE) from Overweight to Neutral and lowers the price target from $2 to $1.
Barrington Research Downgrades Fluent to Market Perform
Barrington Research analyst James Goss downgrades Fluent (NASDAQ:FLNT) from Outperform to Market Perform.
B of A Securities Downgrades Medical Properties Trust to Neutral, Announces $10 Price Target
B of A Securities analyst Joshua Dennerlein downgrades Medical Properties Trust (NYSE:MPW) from Buy to Neutral and announces $10 price target.
TD Cowen Downgrades Oak Street Health to Market Perform, Raises Price Target to $39
TD Cowen analyst Gary Taylor downgrades Oak Street Health (NYSE:OSH) from Outperform to Market Perform and raises the price target from $34 to $39.
SVB Leerink Downgrades Decibel Therapeutics to Market Perform, Lowers Price Target to $2
SVB Leerink analyst Mani Foroohar downgrades Decibel Therapeutics (NASDAQ:DBTX) from Outperform to Market Perform and lowers the price target from $7 to $2.